EGFR and neoplasm: The paper by Quian et al. [80] demonstrated that EGFR-positive tumor xenografts in animal models can be targeted and detected in vivo using SERS and biocompatible/nontoxic gold NPs with single-chain variable fragment antibodies as tumor-targeting ligands, organic dyes as reporters, and thiol-modified polyethylene glycols as stabilizers.